4.2 Article

Continuous Reduced Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution's Three Decade Experience

期刊

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 20, 期 8, 页码 1217-1223

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2014.04.021

关键词

Allogeneic stem cell transplantation; Nonrelapse mortality; Overall survival

资金

  1. Association pour la Recherche sur le Cancer (ARC) [3175]
  2. Fondation de France
  3. Fondation contre la Leucemie
  4. Agence de Biomedecine
  5. Association Cent pour Sang la Vie
  6. Association Laurette Fuguain
  7. International Research Group on Unrelated Hematopoietic Stem Cell Transplantation (IRGHET)
  8. Ligue contre le Cancer Grand-Ouest
  9. French National Cancer Institute (PHRC, INCa)
  10. Association for Training, Education and Research in Hematology, Immunology and Transplantation
  11. Region Pays de Loire

向作者/读者索取更多资源

This study analyzed changes in patients, transplantation, graft characteristics, and outcome among 827 patients who received their first allo-SCT in a single center between 1983 and 2010. In the 2001 to 2010 decade, compared with the 1983 to 1990 and 1991 to 2000 decades, patients were significantly older and presented with higher risk diseases, reduced intensity conditioning and alternative donors were used more often, and stem cell sources changed from bone marrow to peripheral blood stem cells and cord blood. In the 2001 to 2010 decade, we dbserved a significant decrease in nonrelapse mortality (NRM) (P = .0007 and P < .0001, respectively) and an increase in relapse incidence (P = .04 and P = .009, respectively), but overall survival (OS) was increased (P = .11 and P = .009, respectively), and there was a trend towards an increased progression-free survival (P = .30 and P = .09, respectively), as compared with the 1983 to 1990 and 1991 to 2000 decades. Chronic graft-versus-host disease (GVHD) was significantly increased, whereas grades III to IV acute GVHD remained stable. These data suggest that, despite the fact that older and higher risk patients with more comorbidities underwent transplantation in the last 10 years, NRM decreased while the incidence of relapse increased and the OS improved. (C) 2014 American Society for Blood and Marrow Transplantation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biophysics

Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel, Myriam Labopin, Mohamed Houhou, Denis Caillot, Juergen Finke, Didier Blaise, Nathalie Fegueux, Mark Ethell, Jan J. Cornelissen, Edouard Forcade, Ibrahim Yakoub-Agha, Federico Lussana, Johan Maertens, Jean Henri Bourhis, Pavel Jindra, Norbert Claude Gorin, Arnon Nagler, Mohamad Mohty

Summary: For elderly patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1), autologous hematopoietic cell transplantation (auto-HCT) may be considered as an alternative to reduced intensity conditioning allogeneic HCT (RIC-allo-HCT). A retrospective study compared outcomes of RIC-allo-HCT from matched sibling donors (MSD) or matched unrelated donors (MUD) with auto-HCT for patients aged 55 years or more. While the probabilities of leukemia-free survival (LFS) and overall survival (OS) were not significantly different between RIC-allo-HCT and auto-HCT, the risk of non-relapse mortality (NRM) was higher for both MSD-HCT and MUD-HCT, and for MUD-HCT, the chance of LFS and OS was lower.

BONE MARROW TRANSPLANTATION (2023)

Letter Biophysics

Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up

Tamim Alsuliman, Nicolas Stocker, Elise Corre, Remy Dulery, Simona Sestili, Laure Ricard, Florent Malard, Mohamad Mohty, Paul Coppo, Zora Marjanovic

Summary: Patients with high-risk lymphoma received R-COPADM and CYVE treatment, followed by ASCT if suitable. The study showed the efficacy and acceptable safety profile of this regimen, with a 87% overall survival rate and a 83% progression-free survival rate at 46 months of follow-up. These results suggest the potential benefit of this treatment approach for high-risk lymphoma patients.

BONE MARROW TRANSPLANTATION (2023)

Letter Hematology

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Dai Chihara, Luuk Gras, Nienke Zinger, Nicolaus Kroeger, Jiri Mayer, Jakob Passweg, Regis Peffault de Latour, Jenny Byrne, William Krueger, Jan-Paul Bohn, Uwe Platzbecker, Igor Wolfgang Blau, Francesca Bonifazi, Grzegorz Helbig, Andrew McDonald, Martin Mistrik, Mohamad Mohty, Ron Ram, Jaime Sanz, Carlos Vallejo Llamas, Robert J. Kreitman, Patrick J. Hayden, Donal McLornan, Olivier Tournilhac, Michel van Gelder, Ibrahim Yakoub-Agha

HAEMATOLOGICA (2023)

Article Hematology

Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT

Alexandros Spyridonidis, Myriam Labopin, Bipin Savani, Sebastian Giebel, Gesine Bug, Stefan Schoenland, Nicolaus Kroeger, Matthias Stelljes, Thomas Schroeder, Andrew McDonald, Igor-Wolfgang Blau, Martin Bornhaeuser, Montse Rovira, Wolfgang Bethge, Andreas Neubauer, Arnold Ganser, Jean Henri Bourhis, Matthias Edinger, Bruno Lioure, Gerald Wulf, Kerstin Schaefer-Eckart, Mutlu Arat, Zinaida Peric, Christoph Schmid, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty

Summary: In this registry-based study, the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) were compared. The study found that the total dose of total body irradiation (TBI) did not influence the survival outcomes for patients, regardless of whether they received a standard 12-Gray or lower 8-Gray dose.

HEMASPHERE (2023)

Article Hematology

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socie, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser

Summary: Systemic steroids are the first-line treatment for acute graft-versus-host disease, but about 50% of patients become steroid-refractory or dependent. Ruxolitinib is the only approved therapy for these patients and has shown superior efficacy compared with the best available therapy in a clinical trial.
Editorial Material Hematology

IL-22, a new beacon in gastrointestinal aGVHD

Mohamad Mohty, Florent Malard

Summary: This study evaluated the safety and efficacy of a novel recombinant human interleukin-22 (IL-22) dimer in combination with systemic corticosteroids for the treatment of newly diagnosed gastrointestinal acute graft-versus-host disease (GVHD). The results showed that the overall response rate of the treatment group at day 28 was 70%.
Review Biophysics

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)

Mohamad Mohty, Florent Malard, Ahmed S. Alaskar, Mahmoud Aljurf, Mutlu Arat, Peter Bader, Frederic Baron, Ali Bazarbachi, Didier Blaise, Eolia Brissot, Fabio Ciceri, Selim Corbacioglu, Jean-Hugues Dalle, Fiona Dignan, Anne Huynh, Michelle Kenyon, Arnon Nagler, Antonio Pagliuca, Zinaida Peric, Paul G. Richardson, Annalisa Ruggeri, Tapani Ruutu, Ibrahim Yakoub-Agha, Rafael F. Duarte, Enric Carreras

Summary: Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can occur after hematopoietic cell transplantation (HCT). The European Society for Blood and Marrow Transplantation (EBMT) has recently updated the definition and severity grading system for SOS/VOD in adult patients. The aim of this work is to provide an update on the diagnosis, severity assessment, pathophysiology, and treatment of SOS/VOD in adult patients.

BONE MARROW TRANSPLANTATION (2023)

Article Biophysics

Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Helene Labussiere-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Peter Remenyi, Yener Koc, Jaime Sanz, Fabio Ciceri, Mohamad Mohty

Summary: Retrospective evaluation of transplant outcomes in adult AML patients undergoing allo-HCT in CR2 showed that post-transplant cyclophosphamide is an effective method for GVHD prophylaxis.

BONE MARROW TRANSPLANTATION (2023)

Article Biophysics

Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT

Frederic Baron, Annalisa Ruggeri, Christophe Peczynski, Myriam Labopin, Jean-Henri Bourhis, Mauricette Michallet, Patrice Chevallier, Jaime Sanz, Edouard Forcade, Riccardo Saccardi, Victoria Potter, Eliane Gluckman, Arnon Nagler, Mohamad Mohty

Summary: This study assessed the outcomes of patients who experienced graft failure after umbilical cord blood transplantation (CBT). It included a total of 87 patients and found that the cumulative incidence of relapse and nonrelapse mortality at 1-year was 35% and 37% respectively. Among patients who underwent salvage second transplantation, the 1-year and 2-year overall survival rates were 41% and 34% respectively. The study also identified complete remission and reduced-intensity conditioning as factors associated with better overall survival.

BONE MARROW TRANSPLANTATION (2023)

Letter Biophysics

Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party

M. A. de Witte, J. E. Mooyaart, J. D. Hoogenboom, C. Chabannon, F. Malard, A. Ruggeri, J. Kuball

BONE MARROW TRANSPLANTATION (2023)

Article Hematology

Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission

Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty

Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study

Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty

Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).

CANCER (2023)

Review Oncology

Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies

Jean El-Cheikh, Nour Moukalled, Florent Malard, Ali Bazarbachi, Mohamad Mohty

Summary: With the improvement in cancer treatment, including multiple myeloma, the risk of cardiovascular disease in patients has significantly increased, especially in elderly patients and those with additional risk factors. The risk factors can be patient-, disease-, and/or therapy-related, and they impact survival negatively. About 7.5% of multiple myeloma patients experience cardiovascular events, with varied risks depending on patient characteristics and treatment used. Cardiac toxicities have been associated with immunomodulatory drugs, proteasome inhibitors, and other agents, highlighting the importance of comprehensive cardiac evaluation and surveillance strategies for early detection and management.

BLOOD CANCER JOURNAL (2023)

Article Biophysics

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study

Tapani Ruutu, Christophe Peczynski, Mohamed Houhou, Emmanuelle Polge, Mohamad Mohty, Nicolaus Kroeger, Ivan Moiseev, Olaf Penack, Nina Salooja, Helene Schoemans, Rafael F. Duarte, Thomas Schroeder, Jakob Passweg, Gerald G. Wulf, Arnold Ganser, Simona Sica, Mutlu Arat, Urpu Salmenniemi, Annoek E. C. Broers, Jean Henri Bourhis, Alessandro Rambaldi, Johan Maertens, Kazimierz Halaburda, Tsila Zuckerman, Helene Labussiere-Wallet, Grzegorz Basak, Christian Koenecke, Zinaida Peric

Summary: The study investigated the incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers. It included 71 participating centers with a total of 2886 allogeneic transplantations and 93 cases of VOD/SOS in 2018. The findings showed a low incidence of VOD/SOS and a predominance of severe and very severe grades, indicating the importance of early diagnosis and treatment to improve outcomes.

BONE MARROW TRANSPLANTATION (2023)

Letter Biophysics

Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Giorgia Battipaglia, Jarl E. Mooyaart, Ralf Meyer, Mohamad Mohty, Alicja Sadowska-Klasa, Oleg Goloshchapov, Franco Locatelli, Jan Styczynski, Jiri Pavlu, Jaroslaw Dybko, Gleb Bronin, Urpu Salmenniemi, Pavel Jindra, Jorinde D. Hoogenboom, Jurgen Kuball, Annalisa Ruggeri, Florent Malard

BONE MARROW TRANSPLANTATION (2023)

暂无数据